Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
On Sept. 8, 2025, Femasys announced it has received approval from the New Zealand Medicines and Medical Devices…
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
On Jun. 25, 2025, Femasys announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation of…
Biology | FDA | Women's Health
FDA required the first patient package insert: oral contraceptives must contain information for the patient about specific risks and benefits
In 1970, the U.S. Food and Drug Administration (FDA) required the first patient package insert: oral contraceptives must contain…